FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2554664411> ?p ?o ?g. }

• W2554664411 abstract "Abstract Abstract 1130 Poster Board I-152 Background Nilotinib is a selective and potent BCR-ABL inhibitor, with in vitro activity against most BCR-ABL mutants (excluding T315I) indicated for the treatment of patients with Philadelphia chromosome positive (Ph+) CML in CPor AP resistant or -intolerant to prior therapy, including imatinib. In a previous analysis of nilotinib in patients with BCR-ABL mutations, mutations occurring at three specific amino acid residues (E255K/V, Y253H, and F359C/V) were shown to be associated with less favorable response to nilotinib. The current analysis is based on mature data with a minimum follow-up of 24-months for all patients. Outcomes of patients at 24 months were analyzed by mutation type. Methods Imatinib-resistant CML-CP (n = 200) and CML-AP (n = 93) patients were subdivided into the following mutational subsets: no mutation, sensitive mutations (including mutations with unknown in vitro IC50). or E255K/V, Y253H, or F359C/V mutations at baseline. Patients with mutations of unknown in vitro sensitivity were classified as sensitive in this analysis based on a previous finding that patients with these mutations responded similarly to nilotinib as patients with sensitive mutation. Patients with baseline T315I mutations were excluded from this analysis. Patient groups were analyzed for kinetics and durability of cytogenetic and molecular response to nilotinib, as well as event-free survival (EFS), defined as loss of hematologic or cytogenetic response, progression to AP/BC, discontinuation due to disease progression, or death, and overall survival (OS). Results In CML-CP and -AP patients with no mutation, sensitive mutations, or E255K/V, Y253H, or F359C/V mutations, hematologic, cytogenetic and molecular responses are provided in the Table. Overall, patients with no mutations responded similarly to patients with sensitive mutations, whereas patients with E255K/V, Y253H, or F359C/V mutations had less favorable responses. This correlation was observed in both CML-CP and CML-AP patients, respectively. Median time to CCyR was 3.3 months (range, 1.0–26.7) for CML-CP patients with no mutations, and 5.6 months (range, 0.9–22.1) for patients with sensitive mutations. At 24 months, CCyR was maintained in 74% of CML-CP patients with no mutation and in 84% of patients with sensitive mutations. One patient with CML-CP and an E255K mutation achieved CCyR at 25 months and maintained until last assessment at 30 months. Median time to MMR was similar at 5.6 months (range, 0.9–25.8) for CML-CP patients with no mutations and 5.6 months (range, 2.7–22.1) for patients with sensitive mutations. No patient with a less sensitive mutation achieved MMR. Median EFS and 24-month estimated OS rate are provided in the Table. Conclusions Imatinib-resistant CML-CP and CML-AP patients treated with nilotinib therapy with BCR-ABL mutations (excluding E255K/V, Y253H, or F359C/V) achieved rapid and durable cytogenetic responses, and estimated EFS and OS at 24 months similar to that of patients with no mutations, respectively. Patients with E255K/V, Y253H, or F359C/V mutations had lower and less-durable responses and shorter EFS than patients with sensitive mutations. Alternative therapies may be considered for patients with these uncommon mutations (E255K/V, Y253H, and F359C/V). Disclosures Radich: Novartis: Consultancy, Honoraria, Research Funding. Hochhaus:Novartis: Research Funding. Branford:Novartis Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol-Myers Squibb: Honoraria, Research Funding. Shou:Novartis: Employment. Haque:Novartis: Employment. Woodman:Novartis: Employment. Kantarjian:Novartis: Research Funding. Hughes:Bristol-Myers Squibb: Advisor, Honoraria, Research Funding; Novartis: Advisor, Honoraria, Research Funding. Kim:Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Wyeth: Research Funding. Saglio:Novartis: Consultancy, Speakers Bureau; BMS: Consultancy, Speakers Bureau." @default.
• W2554664411 created "2016-11-30" @default.
• W2554664411 creator A5000192349 @default.
• W2554664411 creator A5000529499 @default.
• W2554664411 creator A5008647856 @default.
• W2554664411 creator A5011454613 @default.
• W2554664411 creator A5016041461 @default.
• W2554664411 creator A5021957877 @default.
• W2554664411 creator A5026190297 @default.
• W2554664411 creator A5032812083 @default.
• W2554664411 creator A5035964802 @default.
• W2554664411 creator A5049971021 @default.
• W2554664411 creator A5051637916 @default.
• W2554664411 creator A5073761054 @default.
• W2554664411 creator A5088450042 @default.
• W2554664411 creator A5089541690 @default.
• W2554664411 creator A5090435894 @default.
• W2554664411 date "2009-11-20" @default.
• W2554664411 modified "2023-09-29" @default.
• W2554664411 title "Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations." @default.
• W2554664411 doi "https://doi.org/10.1182/blood.v114.22.1130.1130" @default.
• W2554664411 hasPublicationYear "2009" @default.
• W2554664411 type Work @default.
• W2554664411 sameAs 2554664411 @default.
• W2554664411 citedByCount "2" @default.
• W2554664411 countsByYear W25546644112017 @default.
• W2554664411 crossrefType "journal-article" @default.
• W2554664411 hasAuthorship W2554664411A5000192349 @default.
• W2554664411 hasAuthorship W2554664411A5000529499 @default.
• W2554664411 hasAuthorship W2554664411A5008647856 @default.
• W2554664411 hasAuthorship W2554664411A5011454613 @default.
• W2554664411 hasAuthorship W2554664411A5016041461 @default.
• W2554664411 hasAuthorship W2554664411A5021957877 @default.
• W2554664411 hasAuthorship W2554664411A5026190297 @default.
• W2554664411 hasAuthorship W2554664411A5032812083 @default.
• W2554664411 hasAuthorship W2554664411A5035964802 @default.
• W2554664411 hasAuthorship W2554664411A5049971021 @default.
• W2554664411 hasAuthorship W2554664411A5051637916 @default.
• W2554664411 hasAuthorship W2554664411A5073761054 @default.
• W2554664411 hasAuthorship W2554664411A5088450042 @default.
• W2554664411 hasAuthorship W2554664411A5089541690 @default.
• W2554664411 hasAuthorship W2554664411A5090435894 @default.
• W2554664411 hasConcept C126322002 @default.
• W2554664411 hasConcept C143998085 @default.
• W2554664411 hasConcept C2777413986 @default.
• W2554664411 hasConcept C2777583451 @default.
• W2554664411 hasConcept C2778461978 @default.
• W2554664411 hasConcept C2778729363 @default.
• W2554664411 hasConcept C2779536868 @default.
• W2554664411 hasConcept C2909065710 @default.
• W2554664411 hasConcept C3019892230 @default.
• W2554664411 hasConcept C502942594 @default.
• W2554664411 hasConcept C71924100 @default.
• W2554664411 hasConceptScore W2554664411C126322002 @default.
• W2554664411 hasConceptScore W2554664411C143998085 @default.
• W2554664411 hasConceptScore W2554664411C2777413986 @default.
• W2554664411 hasConceptScore W2554664411C2777583451 @default.
• W2554664411 hasConceptScore W2554664411C2778461978 @default.
• W2554664411 hasConceptScore W2554664411C2778729363 @default.
• W2554664411 hasConceptScore W2554664411C2779536868 @default.
• W2554664411 hasConceptScore W2554664411C2909065710 @default.
• W2554664411 hasConceptScore W2554664411C3019892230 @default.
• W2554664411 hasConceptScore W2554664411C502942594 @default.
• W2554664411 hasConceptScore W2554664411C71924100 @default.
• W2554664411 hasLocation W25546644111 @default.
• W2554664411 hasOpenAccess W2554664411 @default.
• W2554664411 hasPrimaryLocation W25546644111 @default.
• W2554664411 hasRelatedWork W142438241 @default.
• W2554664411 hasRelatedWork W2467542547 @default.
• W2554664411 hasRelatedWork W2522083081 @default.
• W2554664411 hasRelatedWork W2527425031 @default.
• W2554664411 hasRelatedWork W2527518979 @default.
• W2554664411 hasRelatedWork W2529552526 @default.
• W2554664411 hasRelatedWork W2530065787 @default.
• W2554664411 hasRelatedWork W2547001948 @default.
• W2554664411 hasRelatedWork W2564749987 @default.
• W2554664411 hasRelatedWork W2568682439 @default.
• W2554664411 hasRelatedWork W2581024504 @default.
• W2554664411 hasRelatedWork W2586836978 @default.
• W2554664411 hasRelatedWork W2589531275 @default.
• W2554664411 hasRelatedWork W2592309829 @default.
• W2554664411 hasRelatedWork W2593275108 @default.
• W2554664411 hasRelatedWork W2618646545 @default.
• W2554664411 hasRelatedWork W2915035827 @default.
• W2554664411 hasRelatedWork W3011418178 @default.
• W2554664411 hasRelatedWork W3080834949 @default.
• W2554664411 hasRelatedWork W3174186587 @default.
• W2554664411 isParatext "false" @default.
• W2554664411 isRetracted "false" @default.
• W2554664411 magId "2554664411" @default.
• W2554664411 workType "article" @default.